Search Results for "Insomnia"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Insomnia. Results 11 to 20 of 53 total matches.

Comparison Table: Drugs for Alzheimer's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022  (Issue 1657)
pruritus, dermatitis and pain, muscle spasms, insomnia, abdominal pain, constipation, diarrhea ...
View the Comparison Table: Drugs for Alzheimer's Disease
Med Lett Drugs Ther. 2022 Aug 22;64(1657):e136-7 |  Show IntroductionHide Introduction

Cariprazine (Vraylar) for Adjunctive Treatment of Depression

   
The Medical Letter on Drugs and Therapeutics • May 29, 2023  (Issue 1677)
, fatigue, nausea, insomnia, extrapyramidal symptoms, and somnolence are common. Dosage: 1.5 mg PO once ...
The FDA has approved the second-generation antipsychotic drug cariprazine (Vraylar — Abbvie) for adjunctive treatment of major depressive disorder (MDD) in adults. Cariprazine was previously approved for treatment of schizophrenia and bipolar depression, and for acute treatment of manic or mixed episodes associated with bipolar I disorder.
Med Lett Drugs Ther. 2023 May 29;65(1677):84-6   doi:10.58347/tml.2023.1677c |  Show IntroductionHide Introduction

Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023  (Issue 1679)
dementia. Safety: Nasopharyngitis, urinary tract infection, dizziness, headache, somnolence, insomnia ...
The FDA has approved the oral second-generation antipsychotic drug brexpiprazole (Rexulti – Otsuka/Lundbeck) for once-daily treatment of agitation associated with dementia due to Alzheimer's disease (AD). Brexpiprazole is the first drug to be approved in the US for this indication. It is also approved for treatment of schizophrenia and as an adjunct to antidepressants for treatment of major depressive disorder.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):99-101   doi:10.58347/tml.2023.1679b |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
▶ May be an option for patients with comorbid insomnia 7.60 Nortriptyline – generic 25-150 mg PO once/day 12.70 ...
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e100-2   doi:10.58347/tml.2023.1678c |  Show IntroductionHide Introduction

Once-Weekly or Once-Monthly Subcutaneous Buprenorphine (Brixadi) for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023  (Issue 1683)
such as headache, constipation, nausea, insomnia, and injection-site pain, erythema, and pruritus was similar ...
The FDA has approved a subcutaneously injected, extended-release formulation of the mu-opioid receptor partial agonist and kappa-opioid receptor antagonist buprenorphine (Brixadi – Braeburn) for once-weekly or once-monthly treatment of moderate to severe opioid use disorder. Brixadi is the second subcutaneously injected buprenorphine formulation to be approved in the US; Sublocade, which is administered once monthly, was the first. Buprenorphine is also available for treatment of opioid use disorder in sublingual formulations with and without the opioid antagonist...
Med Lett Drugs Ther. 2023 Aug 21;65(1683):133-5   doi:10.58347/tml.2023.1683c |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Weight Management (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025  (Issue 1734)
, and insomnia. Impairment of cognition, attention, concentration, and memory has also been reported ...
View the Comparison Table: Some Drugs for Weight Management
Med Lett Drugs Ther. 2025 Aug 4;67(1734):e127-30   doi:10.58347/tml.2025.1734b |  Show IntroductionHide Introduction

Ashwagandha Supplements

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021  (Issue 1619)
of ashwagandha (Withania somnifera) root extract in insomnia and anxiety: a double-blind, randomized, placebo ...
Ashwagandha is an herb extracted from the roots of an evergreen shrub (Withania somnifera) found in India that has been used as a "tonic" for centuries. No specific constituent has been identified as an active ingredient. Herbal supplements containing ashwagandha, which is also known as winter cherry and Indian ginseng, are widely promoted now in the US for treatment of pain, anxiety, stress, fatigue, sleep disturbances, cognitive decline, diabetes, arthritis, male infertility, and various cancers.
Med Lett Drugs Ther. 2021 Mar 8;63(1619):39-40 |  Show IntroductionHide Introduction

Dextromethorphan/Bupropion (Auvelity) for Depression

   
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022  (Issue 1666)
mouth, sexual dysfunction, hyperhidrosis, anxiety, constipation, decreased appetite, and insomnia ...
The FDA has approved an extended-release fixed-dose combination of dextromethorphan and bupropion (Auvelity – Axsome) for treatment of major depressive disorder (MDD) in adults.
Med Lett Drugs Ther. 2022 Dec 26;64(1666):201-3 |  Show IntroductionHide Introduction

Clonidine Oral Suspension (Onyda XR) for ADHD

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024  (Issue 1718)
hypotension, irritability, nightmares, insomnia, constipation, and dry mouth. Rebound hypertension can occur ...
The FDA has approved Onyda XR (Tris), an extended-release (ER) oral suspension formulation of the alpha2-adrenergic agonist clonidine, for use as monotherapy or as an adjunct to stimulant therapy for treatment of attention-deficit/hyperactivity disorder (ADHD) in children ≥6 years old. Clonidine ER tablets have been available for years for treatment of ADHD in children 6-17 years old.
Med Lett Drugs Ther. 2024 Dec 23;66(1718):205-6   doi:10.58347/tml.2024.1718d |  Show IntroductionHide Introduction

Isatuximab (Sarclisa) for Multiple Myeloma (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024  (Issue 1717)
, rash, infusionrelated reactions, insomnia, and COVID-19 infection. Neutropenia, secondary primary ...
Isatuximab-irfc (Sarclisa – Sanofi), a CD38-directed cytolytic antibody, has been approved by the FDA for treatment of newly diagnosed multiple myeloma in adults who are not eligible for autologous stem cell transplantation (ASCT). The drug was approved earlier for treatment of relapsed or treatment-refractory multiple myeloma.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):e200-1   doi:10.58347/tml.2024.1717e |  Show IntroductionHide Introduction